
Tasigna (Nilotinib): A Forward Leap in CML Treatment
Ongoing myeloid leukemia (CML) has for some time been a provoking illness to treat. Be that as it may, the scene of CML treatment changed decisively with the presentation of Tasigna (nilotinib). This designated treatment, otherwise called a tyrosine kinase inhibitor (TKI), has arisen as a weighty choice in the administration of this hematologic…